News

Boston Scientific Corp. has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus valve system in patients with severe aortic stenosis and...

trinity, transcatheter technologies

Transcatheter Technologies GmbH has announced that results of a first-in-human clinical study of its TRINITY system have been published ahead of print publication in the July issue of the peer-...

heartmate III, tohratec, heart failure, heart failure treatment

Thoratec Corporation announced that it has begun to enroll patients in the HeartMate III U.S. clinical trial. 

September 26, 2014 — In response to new science showing that complete revascularization of all significantly blocked arteries leads to better outcomes in some heart attack patients, the American...

OCT

The first randomized trial to examine serial optical coherence tomography (OCT) in primary percutaneous coronary intervention (PCI) was reported at the Transcatheter Cardiovascular Therapeutics (...

IVUS, CTOs

A new study found that intravascular ultrasound (IVUS)-guided intervention in patients with chronic total occlusion (CTO) could improve outcomes compared to a conventional angiography-guided...

A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from drug-eluting stents found that EES provided...

A first-of-its kind study comparing the safety and efficacy of biodegradable polymer sirolimus-eluting stents (BP-SES) to durable polymer sirolimus-eluting stents (DP-SES) found that the...

The first large prospective study to examine the effectiveness of laser atherectomy in the treatment of femoropopliteal in-stent restenosis (ISR) found that the procedure combined with...

September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) with everolimus and biolimus eluting stents found that BVS demonstrated...

ABSORB II Study DES Xience Abbot Vascular

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb...

Capricor ALLSTAR Phase I Clinical Trial TCT 2014 Stem Cells Myocardial Regenerat

Capricor Therapeutics Inc. presented an abstract entitled "ALLogeneic Heart STem Cells To Achieve Myocardial Regeneration (ALLSTAR): The Six Month Phase I Safety Results" with an oral presentation...

September 22, 2014 — A first-of-its kind study found that using a cerebral protection device during transcatheter aortic valve replacement (TAVR) can significantly reduce the number and volume of...

According to a new study, patients receiving six months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent (DES) appeared to have similar outcomes to...

Study Blood Thinner Heart Attack Patients

The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers unique insight into the use, safety and effectiveness of blood thinners prasugrel and clopidogrel in...

September 19, 2014 — A new study investigating different durations of triple therapy for anticoagulation after drug-eluting stent (DES) implantation demonstrated that six weeks of drug therapy was...

September 19, 2014 — According to a new study, peritoneal hypothermia is feasible for patients who have suffered ST-segment elevation myocardial infarction (STEMI). However, the procedure was...

PARTNER I Trial TCT 2014 TAVR Heart Valve Repair

New data from a landmark clinical trial found that after five years, transcatheter aortic valve replacement (TAVR) demonstrated a persistent mortality benefit, improved functional status, and...

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The...

BioControl Medical Enrollment INOVATE-HF Study CardioFit System Heart Failure

BioControl Medical announced that it has reached an important clinical trial milestone, reaching 480 randomized subjects — or 70 percent — of the planned 650 subjects with congestive...